Interstitial brachytherapy using permanent seeds is a common modality for the treatment of early stage prostate cancer. It consists of inserting hundreds of radioactive seeds (size of a grain of rice) in the prostate by means of transperineal needles. In this procedure, dose delivery to healthy surrounding organs at risk (OAR) and dose homogeneity within the prostate are of prime concern. Placement errors should therefore be minimized to avoid unacceptable area underdosage or overdosage.
At present, brachytherapy seeds can be loaded with three different radionuclides: iodine-125 (<sup>125</sup>I: 28.37 keV; 59.40 days), palladium-103 (<sup>103</sup>Pd: 20.74 keV; 16.991 days), and cesium-131 (<sup>131</sup>Cs: 30.45 keV; 9.689 days). Long or short term morbidity is the main drawback of <sup>125</sup>I and <sup>131</sup>Cs due to their deeper penetration in the normal tissues. However, both provide a good homogeneity of the dose distribution within the prostate. By contrast, <sup>103</sup>Pd offers a short penetration depth that reduces the dose to OAR. Nevertheless, it could result in cold spot (underdosage) where a recurrence of the cancer could appear.
A compromise had to be found between good implant uniformity and low dose to OAR. We propose therefore to study if the combination of two radionuclides inside the same seed could be a solution. Two mixtures were considered: <sup>103</sup>Pd<sub>0.75</sub>-<sup>125</sup>I<sub>0.25</sub> and <sup>103</sup>Pd<sub>0.25</sub>-<sup>131</sup>Cs<sub>0.75</sub>. The subscripts denote the fractions of internal activity of each radionuclide. The work is subdivided into three steps.
First we adapt the AAPM TG-43U1 dosimetry formalism used by the physician to make multiple-radionuclides sources compatible with Treatment Planning Systems (TPS). Then the dose distributions around the bi-radionuclide seeds are determined. Second, the prescription doses for both sources are derived using the linear quadratic model for tumor cell surviving fraction. They were computed using mono-radionuclide implants as benchmarks. Finally, treatment plans and Dose-Volume Histograms parameters have been computed on real patients virtually implanted with bi-radionuclide seeds and the results were compared with the mono-radionuclide one. These parameters can then be used to evaluate the Normal Tissue Complication Probability (NTCP) of urethra, the most exposed organ at risk in prostate brachytherapy.
First, dosimetry results show that, from a pure physical point of view (i.e. without tissue reponse), the dose distributions of both mixtures lies in between that for <sup>103</sup>Pd and <sup>125</sup>I/<sup>131</sup>Cs. The compromise between homogeneity and reduced dose at large distance can be reached. Second, the averaged prescription doses for the Pd-I mixture are 142<sup>+15</sup><sub>-16</sub>Gy and 142<sup>+6</sup><sub>-8</sub>Gy using <sup>103</sup>Pd and <sup>125</sup>I as benchmarks, respectively. The values for the Pd Cs mixture are 128<sup>+13</sup><sub>-13</sub>Gy and 115<sup>+6</sup><sub>-7</sub>Gy, using <sup>103</sup>Pd and <sup>131</sup>Cs, respectively, as benchmarks. Finally, urethral NTCP results fall in the 19 to 23% range. However, they are affected by large uncertainties, making the comparison difficult. At present, no conclusion could be drawn about the efficiency of bi-radionuclide brachytherapy in comparison with mono-radionuclide using the available models. Permanent seed prostate brachytherapy suffers a lot from the lack of precision on radiobiological modelling parameters. A better knowledge of their values could significantly improve the predicting models and therefore lead to better treatment outcome.
| Identifer | oai:union.ndltd.org:BICfB/oai:fundp.ac.be:ETDFUNDP:FUNDPetd-04102008-183228 |
| Date | 20 March 2008 |
| Creators | Nuttens, Vincent E |
| Contributors | Lucas Stéphane, Nahum Alan E, Huyskens Dominique, Lambin Philippe, Vercauteren Daniel |
| Publisher | FUNDP |
| Source Sets | Bibliothèque interuniversitaire de la Communauté française de Belgique |
| Language | English |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | http://edoc.bib.ucl.ac.be:61/ETD-db/collection/available/FUNDPetd-04102008-183228/ |
| Rights | restricted, J'accepte que le texte de la thèse (ci-après l'oeuvre), sous réserve des parties couvertes par la confidentialité, soit publié dans le recueil électronique des thèses FUNDP. A cette fin, je donne licence à FUNDP : - le droit de fixer et de reproduire l'oeuvre sur support électronique : logiciel ETD/db - le droit de communiquer l'oeuvre au public Cette licence, gratuite et non exclusive, est valable pour toute la durée de la propriété littéraire et artistique, y compris ses éventuelles prolongations, et pour le monde entier. Je conserve tous les autres droits pour la reproduction et la communication de la thèse, ainsi que le droit de l'utiliser dans de futurs travaux. Je certifie avoir obtenu, conformément à la législation sur le droit d'auteur et aux exigences du droit à l'image, toutes les autorisations nécessaires à la reproduction dans ma thèse d'images, de textes, et/ou de toute oeuvre protégés par le droit d'auteur, et avoir obtenu les autorisations nécessaires à leur communication à des tiers. Au cas où un tiers est titulaire d'un droit de propriété intellectuelle sur tout ou partie de ma thèse, je certifie avoir obtenu son autorisation écrite pour l'exercice des droits mentionnés ci-dessus. |
Page generated in 0.0422 seconds